Myeloproliferative neoplasms trials in Netherlands
12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Amsterdam, Utrecht
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 3Taking peopleA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 1/2Taking peopleA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Maastricht
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Taking peopleA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Hoofddorp
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 · EU 2024-511309-47-00 - Phase 2Taking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Groningen
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 3Taking peopleStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Where
- Dordrecht, Enschede, Hoofddorp
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Hoofddorp
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 3Taking peopleAn extension study for patients previously enrolled in studies with pelabresib
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 34 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT06401356 · EU 2023-508950-24-00 - Phase 2Not yet taking people in NetherlandsRuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis
- Where
- Groningen
- Age
- 18 years and over
- People
- 14
- Run by
- Universitair Medisch Centrum Groningen
See details and how to join2024-510926-19-00 · EU 2024-510926-19-00 - Phase 1/2Taking peopleTasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Age
- 18 years and over
- People
- 20 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06605586 · EU 2024-511565-11-00 - No phaseTaking peopleEffect of Phlebotomy on Heartrate in Polycythemia Patients
- Where
- Leiden
- Age
- 18 years and over
- People
- 10
- Run by
- Leiden University Medical Center
See details and how to joinNCT05396170